 Monopar Therapeutics Inc. MNPR Chicago, IL and NorthStar Medical Radioisotopes, LLC Beloit, WI announced today a 5050 collaboration to develop potential Radio-Immuno-Therapeutics RITs to treat severe COVID-19 patients with SARS-CoV-2 infection. Monopar is a clinical-stage biopharmaceutical company and NorthStar is a commercial producer and supplier of medical radioisotopes. This collaboration combines NorthStars expertise in the innovative production, supply, and distribution of important medical radioisotopes with Monopars expertise in therapeutic drug development and its pre-IND stage humanized urokinase plasminogen activator receptor uPAR targeted monoclonal antibody known as MNPR-101, along with a proprietary portfolio of related monoclonal antibodies that target uPAR or its ligand uPA. 